Home
Transdermal and Microneedle Drug Delivery
11 November - 12 November 2024
Transdermal and Microneedle Drug Delivery

Have you considered that microneedle drug delivery systems could revolutionise the future of vaccine and drug administration?

Discover the future of drug delivery at SAE’s 3rd annual Transdermal and Microneedle Drug Delivery conference, where we lead the transition beyond the needle.

Collaborate with forward-thinking experts in a high-level 2-day program, discussing case studies and real-world examples in delivery R&D, vaccine application, and diversifying capabilities.

Transdermal and Microneedle Array Patches (MAPs) are revolutionizing pharmaceutical development, offering unparalleled potency, increased community access, consistent long-term delivery, and advanced diagnostic capabilities, making this technology a frontrunner in enhancing efficacy and global access to transformative products.

FEATURED SPEAKERS

Aleksandra Puton

Aleksandra Puton

Business Manager, Biotts
Mahmoud Ameri

Mahmoud Ameri

Vice President, Emergex USA Corporation
Muhammet Avcil

Muhammet Avcil

Managing Director, Imperial BioScience
Pawel Biernat

Pawel Biernat

Chief Technology Officer and Co-Founder, Biotts
Renske Hesselink

Renske Hesselink

Director MSC Innovations, Coalition for Epidemic Preparedness Innovations (CEPI)
Sanjiv Sharma

Sanjiv Sharma

Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool
Steven Damon

Steven Damon

CEO, Micron Biomedical
Tom Lake

Tom Lake

Senior Vice President, Strategic Alliances and Commercialization, Vaxxas
Waleed Faisal

Waleed Faisal

Project Manager, School of Pharmacy, University College Cork

Aleksandra Puton

Business Manager, Biotts
Aleksandra Puton

Associated with the business for over 10 years, she has competence in project management, marketing and communication supported by many years of cooperation with customers in the pharmaceutical industry. Responsible for marketing and customer acquisition for the unique MTC-Y technology. Graduate of the University of Warsaw.

Brian Pfister

Vice President, Gylden Pharma
Brian Pfister

Dr. Brian Pfister is a Vice President at Emergex USA where he leads US operations. Emergex USA is a wholly owned subsidiary of UK based Emergex Vaccines Holding Limited, a clinical-stage, privately held biotechnology company pioneering the development of 100% synthetic CD8+ T cell-priming immune set-point therapeutic candidates that harness and direct the body’s natural T cell immune response to destroy and to clear pathogen-infected cells in order to provide protection against some of the world’s most urgent health threats. Brian received his Ph.D. in biochemistry from Rush University and M.B.A. from the University of Notre Dame.

Clemens Gunther

Former Senior Expert Nonclinical Safety, Bayer AG
Clemens Gunther

Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany.
 

Dr. Clemens Günther started his professional career in 1990 at Schering AG, Berlin-Germany. From 2007 to 2013, he was Director and Head of Global Preclinical Development at Intendis GmbH, branded later-on as Bayer Dermatology. In this position, he was responsible for Nonclinical Safety for the marketed product portfolio of Bayer Dermatology as well as the global preclinical development strategy including human DMPK for development and life cycle management projects.
After integration of Intendis into Bayer in 2013, he became Director Nonclinical Safety Consumer Care and later-on Senior Expert Nonclinical Safety within the Division of Bayer Pharmaceuticals. He held this position until June 2024.
 

Dr. Clemens Günther gained about 35 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products including Transdermal Therapeutic Systems. His expertise includes also the Toxicological Risk Assessment of impurities as well as extractables and leachables.
 

Conor O Mahony

Principal Researcher, Tyndall National Institute
Conor O Mahony

Dr. Conor O’Mahony is a Principal Researcher with the Tyndall National Institute, and an Adjunct Professor at Chongqing Technology and Business University, China. He is currently leading a team focussed on the development of Micro Transdermal Interface Platforms (MicroTIPs) – high-value, wearable systems that combine elements of microneedle devices for transdermal delivery and diagnostics, self-awareness and communications capabilities. These ‘smart patches’ interact with the outermost skin layers in a minimally invasive manner, and will blur the lines between implantable medical devices and the current generation of wearable electronics.

James Birchall

Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences , Cardiff University
James Birchall

James Birchall is Professor of Pharmaceutical Sciences and Deputy Head of the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Professor Birchall graduated from Bath University in 1993 and completed his PhD researching drug and DNA delivery systems in 1998 (Cardiff University). Current research includes pulmonary drug delivery and microneedle delivery of molecules, macromolecules, vaccines, auto-antigens and cells into skin for therapeutic, immunisation or immunotherapy applications.

Professor Birchall has acted as Associate Editor of Critical Reviews in Therapeutic Drug Carrier Systems, a member of the Editorial Board of Expert Review of Medical Devices, a temporary advisor to the WHO and an expert advisor to the British Pharmacopoeia and conducted research funded by the EU, DFID, Bill and Melinda Gates Foundation, NIH, Wellcome Trust, EPSRC, MRC, Welsh Government, Royal Society, Innovate UK and various charities and pharmaceutical companies.
 

Lakshmi Jayashankar

Biologist, Influenza & Emerging Infectious Diseases, ASPR/BARDA, U.S. Department of Health and Human Services (HHS)
Lakshmi Jayashankar

Dr. Lakshmi Jayashankar is a Program Officer in the Vaccines Branch within the Influenza and Emerging Infectious Disease Division (IEIDD) for the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services. Dr. Jayashankar joined BARDA in January 2020 and maintains a portfolio of contracts for medical countermeasures (MCM) development efforts with a focus incorporating new vaccine technologies that can provide a faster pandemic response. Dr. Jayashankar is also the lead of Project NexGen (PNG), US government’s (USG’s) initiative for the rapid development of the next generation of COVID-19 vaccines and treatments, centralized Immune Assay Laboratory Network line of effort.
Prior to joining BARDA, Dr. Jayashankar served as a scientific officer in the tuberculosis branch in the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Jayashankar has also previously held positions at Infectious Disease Research Institute, Seattle and Vivaldi Biosciences, New York, where she was the lead of the clinical and preclinical immunology teams. Dr. Jayashankar did her post-doctoral training in the Influenza division at Centers for Disease Control and Prevention (CDC) and received her Ph.D. from the Georgia State University, Atlanta.
 

Mahmoud Ameri

Vice President, Emergex USA Corporation
Mahmoud Ameri

Dr. Mahmoud Ameri currently VP at Emergex USA, spearheads microneedle research and operational initiatives at the Fremont site in California. He brings over two decades of expertise in drug delivery, preclinical and clinical development of combination products. A co-founder of Zosano Pharma he played a crucial role in the development of the microneedle technology. Prior to that he was a key innovator at Alza/J&J co-inventing the microneedle transdermal system. Dr. Ameri earned his PhD from the University of Manchester, School of Pharmacy in the United Kingdom.

Mateusz Hasso-Agopsowicz

Technical Officer, World Health Organization
Mateusz Hasso-Agopsowicz

Dr Mateusz Hasso-Agopsowicz is a Technical Officer in the Department of Immunization, Vaccines and Biologicals (IVB) at the World Health Organization (WHO). He holds a PhD in Vaccine Immunology from the London School of Hygiene and Tropical Medicine (LSHTM). Dr Mateusz leads theme areas on the role of vaccines in reducing antimicrobial resistance (AMR), prioritisation of vaccines for research and development, and supporting the development of vaccine-microarray patches (MAPs). MAPs are priority innovation for WHO and together with partners WHO is developing tools and technical products to advance development of MAPs.

Max Dixon

Lead Applied Sciences Engineer, Crux Product Design
Max Dixon

Lead Applied Sciences Engineer at Crux Product Design, Max completed his PhD in Advanced Composites at the Bristol Composites Institute in 2019. With a background in aerospace engineering, Max leverages his technical skills in complex product design to help de-risk development programs for medical devices, surgical tools, and consumer products. He’s a strong advocate for numerical tools such as digital twins, for their ability to provide early insights where traditional engineering techniques may fall short, resulting in more robust products/solutions. For medical devices, this approach supports faster time-to-market and enhances patient outcomes. Within the pharmaceutical industry, Max has led innovative projects across blue-sky R&D, device assessments, root-cause analysis, early ideation, and production line optimisation. His experience spans the development of diverse medical products, including auto-injectors, on-body devices, pen injectors, surgical stents, dry powder inhalers, primary containers, needle safety devices, and secondary packaging.

Michael Ray

Senior Director Regulatory Affairs, Corium Innovations
Michael Ray

Michael Ray is an industry veteran who has over 47 years of experience with various business roles in the medical device and pharmaceutical industries. Starting out as senior chemist working at a small contract testing laboratory and then moving on to Key Pharmaceuticals as manager Analytical Services where he gained experience with extended-release oral, parenteral, cosmetic and transdermal products. After Key Pharmaceuticals was purchased by Schering Plough, he moved onto hiMedics a drug device technology company as director of analytical and regulatory. Next, he cofounded a specialty service company, Guidelines Integrated Services, which specialized in the analytical testing of modified delivery systems and providing regulatory support for over 200 companies. After the purchase of GIS, he moved onto Corium International where he started out as director AR&D working on all of Corium’s products ranging from the development of its Corplex transdermal, MicroCor microneedle and MicroJet fluid injection technologies. Currently he serves as Senior Director Regulatory Affairs in Corium Innovations R&D group leading the development of its novel transdermal systems.

Muhammet Avcil

Managing Director, Imperial BioScience
Muhammet Avcil

Dr Muhammet Avcil gained his honours degree in Chemistry and an MSc in Molecular Synthesis (Organic Syntheses) from the University of Sussex. After his MSc, He worked as a Research Assistant at the University of Sussex. He conducted his PhD research at the University of Sussex and Imperial College London. He has over 19 years of experience in biotechnology, drug discovery and development, working at universities and senior management positions in various institutions. He is a key figure in the management and strategic development of Imperial Bioscience and continues to get involved in the research and development of the company.
 

Niraj Vasisht

Chief Technology Officer, Corium International
Niraj Vasisht

Nuria Puigmal Dominguez

Founder, LybraBio
Nuria Puigmal Dominguez

Núria Puigmal, PhD, is a cross-disciplinary bioengineer and the co-founder and acting CEO of Lybra Bio, an MIT/Harvard spin out reshaping the treatment of autoimmune skin diseases using microneedle-enabled therapies. Dr. Puigmal conducted her doctoral and post-doctoral research at Harvard Medical School and the Institute for Medical Engineering and Science (IMES) at MIT, working at the intersection between biomaterials and immunology with a focus on transdermal drug delivery systems. Dr. Puigmal was also recently appointed as a Blavatnik Fellow in Life Sciences and Entrepreneurship at the Harvard Business School.

Pawel Biernat

Chief Technology Officer and Co-Founder, Biotts
Pawel Biernat

Co-founder and patent co-author at Biotts, with a PhD in Pharmacy from the Medical University of Wroclaw. A seasoned pharmaceutical technologist with over two decades of experience, specializing in the design of drug active ingredient nanocarriers, transdermal systems, and sterile, non-oral drug formulations. Renowned for contributions to numerous domestic and international scientific publications. At Biotts, excels in creating proprietary formulations and patents for innovative solutions.

Renske Hesselink

Director MSC Innovations, Coalition for Epidemic Preparedness Innovations (CEPI)
Renske Hesselink

Dr Renske Hesselink is a biochemist with a background in the vaccine industry, who is currently working as CMC Technology Lead at CEPI, the Coalition for Epidemic Preparedness Innovations. At CEPI, she works on technology innovations that enable the rapid development and suitably scaled manufacturing of equitably accessible vaccines for outbreak response.


Prior to joining CEPI, Renske worked in the pharmaceutical industry for over 10 years, mainly in formulation, analytical, and drug product development for various vaccines and biologics. She contributed to the Ebola vaccine developed by Janssen during the outbreak in West-Africa, scaling up the process and making vaccine doses available as soon as possible for clinical trials and containment of the epidemic. She also worked on the stabilization of protein- and viral vector-based vaccines against e.g., RSV and HIV. Renske holds an MSc degree in Molecular Sciences from Wageningen University, the Netherlands, and a PhD in Membrane Biology from the University of Leeds, UK.
 

Sanjiv Sharma

Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool
Sanjiv Sharma

Sanjiv Sharma is currently a Senior Lecturer in Infectious Diseases and Antimicrobial Resistance in the David Price Evans Global Health and Infectious Diseases Group at the University of Liverpool's Department of Pharmacology & Therapeutics within the Institute of Systems, Molecular and Integrative Biology. He is a Fellow of the Royal Society of Chemistry and the Higher Education Academy.

He trained as a chemist, holding degrees from Dr. Hari Singh Gour University, Sagar, India, and completed his PhD as part of an Indo-European Communities Joint research project in collaboration with the University of Amsterdam and the Regional Research Laboratory (CSIR), India. His research focuses on the development of innovative biosensing and diagnostic technologies, particularly subdermal wearable biosensors, point-of-care devices, and microfluidic diagnostics. He has made significant contributions to the fields of electrochemical biosensors, lab-on-a-chip systems, and transdermal drug and vaccine delivery devices.

He has been instrumental in pioneering low-cost, transdermal biosensing devices, successfully advancing them from the lab to clinical settings. His work has garnered over 3000 citations, with an h-index of 24, and he has published over 85 research articles, conference proceedings, and book chapters. His contributions to biomedical engineering have been recognized through various honors, including the Chevening Technology Fellowship from the British Foreign Office and his election as a Fellow of the Royal Society of Chemistry.

In addition to his academic research, he has been actively involved in several Research Council Committees and has collaborated with various industry partners, including his role as Principal Investigator on multiple high-profile grants. His work has been featured in media outlets such as the BBC, highlighting the impact of his research on public health.

He is also a member of the Royal Society’s Newton International Fellowships Committee and the UKRI Interdisciplinary Assessment College, and has held visiting academic positions, further underscoring his commitment to advancing research and innovation in his field.

Sebastien Henry

EVP of Technical Operations, Micron Biomedical
Sebastien Henry

Sebastien Henry has over 20 years of research, product development, and project management experience in the microneedle and medical device fields including overall product development responsibilities at Porex Surgical, now owned by Stryker, a company that develops, manufactures, and sells craniofacial implants to surgeons in five surgical specialties. He received a BS from the University of Technology of Compiègne (France) and an MS from the Georgia Institute of Technology, both in bioengineering, as well as an MBA from the Georgia Institute of Technology. Mr. Henry has 8 US patents issued or pending and has worked on microneedles projects at Georgia Tech and Micron for over 10 years.

Steven Damon

CEO, Micron Biomedical
Steven Damon

Mr. Damon is an industry veteran who has over 30 years of experience with various business roles in the medical device and pharmaceutical industries. He served as the CEO and President of 4P Therapeutics, a company he founded in 2011 and sold to Nutriband Inc. in 2018. He served as Chairman and President of Absorbable Polymers International, a company he founded in 2003 as a wholly owned subsidiary of DURECT corporation. Steve has held Executive positions in Mergers & Acquisitions, Business Development and Commercial Development for several companies including Femasys, Altea Therapeutics, DURECT and Kimberly-Clark Health Care.
In addition to his role with Micron, Steve serves on the Board of Directors for Temple Therapeutics. He is a long-time member of Georgia Bio and serves on its Board of Directors.
 

Tom Lake

Senior Vice President, Strategic Alliances and Commercialization, Vaxxas
Tom Lake

Tom Lake supports new businesses that improve access to immunizations. He brings vaccine industry experience in Product Development, Manufacturing, and Commercialization.

Waleed Faisal

Project Manager, School of Pharmacy, University College Cork
Waleed Faisal

CEO and founder of ArrayPatch Ltd. Dr. Faisal led several Enterprise Projects, contributing significantly to commercialization strategies, leading to the formation of ArrayPatch Ltd. With over 16 years of experience in multidisciplinary Pharmaceutics projects, he holds a PhD in Pharmaceutics, and was recognized among Ireland’s top 100 healthcare achievers.

Highlights include:

  • Successes in clinical data and vaccine delivery
  • Innovative capabilities and applications of transdermal and microneedle patches
  • Manufacturing challenges and progress
  • Insights and Q&A opportunities with key regulators

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Co-Chairs' Opening Remarks

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

Mahmoud Ameri, Vice President, Emergex USA Corporation

clock

9:10

Dissolving Microneedle Technology for Drug and Vaccine Administration: Closing the Commercialization Gap

Sebastien Henry, EVP of Technical Operations, Micron Biomedical

  • Preclinical and clinical development update
  • Regulatory considerations and strategy
  • Steps towards commercialization including commercial manufacturing scale up

     

  • clock

    9:50

    Modern Strategies of Topical And Transdermal Drug Delivery

    Clemens Gunther, Former Senior Expert Nonclinical Safety, Bayer AG

  • The physiological perspective: Understanding the difference between local, regional, systemic, and targeted drug delivery
  • Microneedles as current area of interest for transdermal drug delivery
  • Bioequivalence concepts for systemic and topical therapy
     

     

  • clock

    10:30

    Morning Break

    clock

    11:00

    Frontiers in Drug Delivery: Macro Trends in Microneedles

  • Overview of Crux capabilities for medical device development
  • Showcase of medical device digital twins 
  • Human Factors techniques for unlocking patient adherence
  • Crux's digital tissues for in silico drug delivery
  • Advanced approaches for visualising drug delivery
  • Max Dixon, Lead Applied Sciences Engineer, Crux Product Design

    clock

    11:30

    Non-Invasive Transdermal Drug Delivery of Peptides and Proteins

  • Expanding the window of transdermal opportunity: delivery of larger molecules like Semaglutide and Insulin
  • Update of pre-clinical results
  • Pawel Biernat, Chief Technology Officer and Co-Founder, Biotts

    Aleksandra Puton, Business Manager, Biotts

    clock

    12:10

    Networking Lunch

    clock

    13:10

    Closing the Chapter: Reflecting on Zosano’s Legacy

    Mahmoud Ameri, Vice President, Emergex USA Corporation

  • Industry Leadership: Zosano played a pivotal role in shaping the industry landscape and influencing competitors
  • Innovation and pioneering: increasing the delivered dose from mg to mg
  • Core values: A culture of continuous innovation, encouraging employees to think creatively and take calculated risks
  • clock

    13:50

    Achieving Next Generation Needle-Free Vaccine Administration

    Tom Lake, Senior Vice President, Strategic Alliances and Commercialization, Vaxxas

  • Maturing HD-MAP technology for vaccine administration
  • Analysing results from recent usability and accessibility studies
  • Evaluating the potential of needle-free vaccine delivery
  • clock

    14:30

    Afternoon Break

    clock

    15:00

    De-risking Development of Transdermal and Microneedle Drug and Vaccine Delivery Technologies

    Lakshmi Jayashankar, Biologist, Influenza & Emerging Infectious Diseases, ASPR/BARDA, U.S. Department of Health and Human Services (HHS)

  • Continued challenges with MAP development
  • Adjuvants for MAP vaccine products
  • Regulatory considerations
  • clock

    15:40

    Academic Panel: Applying Lessons from Vaccination Progress to the Next Generation of Transdermal and Microneedle Delivery

  • Drawing lessons from progress in vaccination trials and development
  • Overviewing key academic avenues of research - expanding the boundaries of drug delivery
  • Commercialising academic progress
  • Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    James Birchall, Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences , Cardiff University

    Waleed Faisal, Project Manager, School of Pharmacy, University College Cork

    Conor O Mahony, Principal Researcher, Tyndall National Institute

    clock

    16:20

    Co-Chairs' Closing Remarks and Close of Day One

    Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    Mahmoud Ameri, Vice President, Emergex USA Corporation

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Co-Chairs' Opening Remarks

    Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    Mahmoud Ameri, Vice President, Emergex USA Corporation

    clock

    9:10

    Exploring important attributes, the potential use-cases and feasibility of introduction of measles and rubella microarray patches (MR-MAPs): insights from nine countries

    Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization

  • How would this innovation be perceived in different countries?
  • What are the potential uses of MAP’s in different areas?
  • What are the benefits of new innovation?
  • What are the pathways for introduction? What data would we need to implement this?
     
  • clock

    9:50

    Transforming Therapeutics through Transdermal and Microneedle Delivery: Accelerating and Innovating Treatments

    Michael Ray, Senior Director Regulatory Affairs, Corium Innovations

  • Clinical development and gaining regulatory approval for the Adlarity patch 
  • Innovative solutions in our Corplex® transdermal platform
  • Applying intradermal delivery to new molecules and body systems
  • Corium’s MicroCOR® Microneedle Technology – Asset Licensing Opportunity
     
  • clock

    10:30

    Morning Break

    clock

    11:00

    Joint Session: Creating MAPs for use in Low- and Middle-Income Countries (LMICs)

  • How to create MAPs suitable for use in LMICs
  • Scaling up MAP manufacturing: Challenges and successes
  • What other antigens should be pursued after Measles-Rubella (MR) MAPS?
  • Steven Damon, CEO, Micron Biomedical

    Tom Lake, Senior Vice President, Strategic Alliances and Commercialization, Vaxxas

    clock

    11:40

    The Role of Vaccine Microarray Patches in CEPI’s 100-Days Mission

    Renske Hesselink, Director MSC Innovations, Coalition for Epidemic Preparedness Innovations (CEPI)

  • Vaccine Microarray Patches (MAPs) and other needle-free delivery technologies can make vaccines more equitably accessible in epidemic and pandemic response situations 
  • Platform technology development is critical for preparedness
  • Speed of development as well as scalability of manufacturing are key to rapid response and equitable access
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Progressing Next-Generation Vaccines using Hollow Microneedle Delivery – Results from the Emergex Vaccines naNO-Dengue and naNO-COVID Phase I Clinical Trial

    Brian Pfister, Vice President, Gylden Pharma

  • Demonstrating successful coating and stability of COVID-19 vaccine on MNP
  • Positive Phase 1 data of DengueTcP treatment
  • Novel proprietary MNP delivery platform
  • clock

    14:00

    Applying the Biomedical Catalyst 2023 Grant to Further Develop Microneedle Patch Technology (MPT)

    Muhammet Avcil, Managing Director, Imperial BioScience

  • Assessing the key advantages of ‘dissolving microstructure’ MPTs
  • Applying cutting-edge technology to transition into clinical stage in the development of MPT medicinal products
  • Reviewing the application of MPT technology to both therapeutic and cosmetic purposes
  • clock

    14:40

    Afternoon Break

    clock

    15:10

    Industry Panel: Approaching and Resolving Practical and Logistical Challenges in Microneedle Delivery Maturation

  • Universal challenges when commercialising research
  • Drawing lessons from previous successes and failures
  • Achieving cost-effective manufacturing at scale
  • Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    Brian Pfister, Vice President, Gylden Pharma

    Sebastien Henry, EVP of Technical Operations, Micron Biomedical

    clock

    16:00

    Co-Chairs' Closing Remarks and Close of Day Two

    Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    Mahmoud Ameri, Vice President, Emergex USA Corporation


    Business Manager
    Biotts
    Vice President
    Gylden Pharma
    Former Senior Expert Nonclinical Safety
    Bayer AG
    Principal Researcher
    Tyndall National Institute
    Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences
    Cardiff University
    Biologist, Influenza & Emerging Infectious Diseases
    ASPR/BARDA, U.S. Department of Health and Human Services (HHS)
    Vice President
    Emergex USA Corporation
    Technical Officer
    World Health Organization
    Lead Applied Sciences Engineer
    Crux Product Design
    Senior Director Regulatory Affairs
    Corium Innovations
    Managing Director
    Imperial BioScience
    Chief Technology Officer
    Corium International
    Founder
    LybraBio
    Chief Technology Officer and Co-Founder
    Biotts
    Director MSC Innovations
    Coalition for Epidemic Preparedness Innovations (CEPI)
    Senior Lecturer in Infectious Diseases and Antimicrobial Resistance
    University of Liverpool
    EVP of Technical Operations
    Micron Biomedical
    CEO
    Micron Biomedical
    Senior Vice President, Strategic Alliances and Commercialization
    Vaxxas
    Project Manager, School of Pharmacy
    University College Cork

    Gold Sponsor

    Supporting Media Partners

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Current Attendee List

    Download

    Speaker Interview - Pawel Biernat

    Download

    Speaker Interview - Brian Pfitser

    Download

    Speaker Interview - Steven Damon

    Download

    Past Attendee List

    Download

    60 seconds with Michael Schrader, Co-Founder & CEO, Vaxess Technologies

    Download

    Past Presentation - Bayer

    Download

    Past Presentation: Nutriband

    Download

    Past Presentation - Starton Therapeutics

    Download

    Letter from the Chairs

    Download

    2024 Brochure

    Download

    Sponsors and Exhibitors


    Crux

    Gold Sponsor
    https://www.cruxproductdesign.com/

    Crux was founded to address challenging technical briefs and deliver compelling solutions for the drug delivery and medical device sectors. Based in Bristol, United Kingdom, our technical team champion evidence-based problem solving, coupling world-class equipment, software and facilities with a scientific approach to maximise success. Be it discovering unmet user needs, developing novel products or deploying new technologies, our team are dedicated to solving our client’s biggest problems..


    Media Partners


    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    The Medicine Maker

    Supporting Media Partners
    https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo


    On Drug Delivery

    Supporting Media Partners
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Pharmacircle

    Supporting Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.